🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the effort against superbug strains of the infection, according to researchers.

A Global Health Concern

The sexually transmitted infection are on the rise globally, with data suggesting more than 82 million new cases each year. Notably increased rates are observed in the African continent and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary step in the context of growing infection rates, the spread of superbugs and the extremely scarce therapeutic options currently available.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has classified it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Receive Clearance

One new antibiotic, marketed under the name Nuzolvence, was authorized by the US FDA in recent days for treating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts hope that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This drug, which is also used to treat urinary tract infections, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This authorization marks a significant shift in the management of highly resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Results and Global Access

As per results published in a major medical journal, the new drug eradicated the vast majority of genital gonorrhoea infections. This puts it on an equal footing with the current standard treatment, which uses an injection and a pill. The study included nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the authority to license and sell the drug in numerous developing nations.

Clinicians on the front lines have expressed hope. Access to a one-pill regimen of this kind is hailed as a "critical tool" for gonorrhoea control. This is deemed essential to alleviate the strain of the disease for people and to prevent the spread of extremely resistant gonorrhoea around the world.